(S)-3-Amino-3-(1H-indol-3-yl)propanoic acid | 329013-06-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (S)-3-Amino-3-(1H-indol-3-yl)propanoic acid
• 英文别名: (3S)-3-amino-3-(1H-indol-3-yl)propanoic acid
• CAS: 329013-06-1
• 化学式: C₁₁H₁₂N₂O₂
• 分子量: 204.22
• InChiKey: VCQANZIIRHWOIU-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  79.1
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：The Johns Hopkins University

  公开号：US20210094933A1

  公开（公告）日：2021-04-01

  The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have great potential as new leads for developing drugs to be used for treating diseases.

  本公开提供了受免疫蛋白配体家族FK506和雷帕霉素天然产物启发的大环化合物。生成包含FK506和雷帕霉素结合结构域的Rapafucin大环化合物库，应具有作为治疗疾病新药的潜力。
• Rapafucin derivative compounds and methods of use thereof
  申请人：The Johns Hopkins University

  公开号：US11066416B2

  公开（公告）日：2021-07-20

  The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have great potential as new leads for developing drugs to be used for treating diseases.

  本公开提供了受天然产物 FK506 和雷帕霉素的免疫嗜蛋白配体家族启发的大环化合物。由含有 FK506 和雷帕霉素结合结构域的大环化合物组成的雷帕霉素库，作为开发用于治疗疾病的药物的新线索，具有巨大的潜力。
• EP2694095A1
  申请人：——

  公开号：EP2694095A1

  公开（公告）日：2014-02-12
• COMPOSITIONS COMPRISING GLUCAGON ANALOGS AND METHODS OF MAKING AND USING THE SAME
  申请人：Longevity Biotech, Inc.

  公开号：EP2694095B1

  公开（公告）日：2018-03-07
• [EN] COMPOSITIONS COMPRISING GLUCAGON ANALOGS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] COMPOSITIONS COMPRENANT DES ANALOGUES DU GLUCAGON ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：LONGEVITY BIOTECH INC

  公开号：WO2012138941A1

  公开（公告）日：2012-10-11

  This invention relates to novel compositions comprising analogs of glucagon, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways, including diabetes and other metabolic disorders. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.